Future prospective, multicenter studies incorporating larger severe AP cohorts, additional biomarkers such as CRP and APACHE II, and multivariate modeling are warranted to validate D-dimer’s suggested clinical utility and to identify actionable threshold values for integration into severity stratification protocols. This evidence concerns the gene CRP and alkaline phosphatase measurement.